IL2RA

Across TCGA pan-cancer cohorts, IL2RA Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IL2RA data layer compared with 24 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher IL2RA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL2RA expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, KICH, and DLBC are the cancer types where IL2RA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.688	<.001	48	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.872	0.464	.031	3	view →
LUAD	DFS	Median	All	0.525	0.813	<.001	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IL2RA–STAD (OS)

Open the STAD breakdown →